



Novel Approaches to Hematologic Malignancies by Immunotherapy

Guest Editor:

Dr. Yosuke Minami

National Cancer Center Hospital
East, Kashiwa 277-8577, Chiba,
Japan

Deadline for manuscript
submissions:

closed (31 May 2021)

Message from the Guest Editor

Dear Colleagues,

The landscape of immunotherapy for the treatment hematologic malignancies (HMs) has become crowded in light of new modalities. Some HMs can escape T-cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/ programmed cell-death protein 1 ligand 1 (PD-L1) immune checkpoint. Therapeutic antibodies that block the PD-1-PD-L1 axis or other types of checkpoint inhibitors induce durable clinical responses against a growing list of various HMs. Chimeric antigen receptor (CAR) T cells, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates (ADCs) are also promising candidates. In this issue, we would like to show the novel immunotherapy in translational research and clinical development for the treatment of HMs.

Dr. Yosuke Minami
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. José L. Quiles

Department of Physiology,
Institute of Nutrition and Food
Technology “Jose Mataix”,
Biomedical Research Center,
University of Granada, Avda.
Conocimiento s/n, 18100 Armilla,
Granada, Spain

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI